Autobio Diagnostics Co Stock Net Income
| 603658 Stock | 40.09 0.11 0.27% |
Autobio Diagnostics Co fundamentals help investors to digest information that contributes to Autobio Diagnostics' financial success or failures. It also enables traders to predict the movement of Autobio Stock. The fundamental analysis module provides a way to measure Autobio Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Autobio Diagnostics stock.
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 1.3 B | 728.7 M | |
| Net Income From Continuing Ops | 1.4 B | 867.8 M | |
| Net Income | 1.4 B | 857.9 M |
Autobio | Net Income |
Autobio Diagnostics Co Company Net Income Analysis
Autobio Diagnostics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Autobio Diagnostics Net Income | 1.22 B |
Most of Autobio Diagnostics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Autobio Diagnostics Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Autobio Operating Income
Operating Income |
|
Based on the recorded statements, Autobio Diagnostics Co reported net income of 1.22 B. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net income for all China stocks is notably lower than that of the firm.
Autobio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Autobio Diagnostics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Autobio Diagnostics could also be used in its relative valuation, which is a method of valuing Autobio Diagnostics by comparing valuation metrics of similar companies.Autobio Diagnostics is currently under evaluation in net income category among its peers.
Autobio Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0705 | ||||
| Profit Margin | 0.28 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 23.04 B | ||||
| Shares Outstanding | 581.01 M | ||||
| Shares Owned By Insiders | 70.16 % | ||||
| Shares Owned By Institutions | 9.38 % | ||||
| Price To Book | 2.77 X | ||||
| Price To Sales | 5.08 X | ||||
| Revenue | 4.44 B | ||||
| Gross Profit | 2.96 B | ||||
| EBITDA | 1.72 B | ||||
| Net Income | 1.22 B | ||||
| Total Debt | 343.3 M | ||||
| Book Value Per Share | 14.69 X | ||||
| Cash Flow From Operations | 1.47 B | ||||
| Earnings Per Share | 2.20 X | ||||
| Target Price | 58.17 | ||||
| Number Of Employees | 5.54 K | ||||
| Beta | -0.009 | ||||
| Market Capitalization | 23.29 B | ||||
| Total Asset | 11.55 B | ||||
| Retained Earnings | 3.8 B | ||||
| Working Capital | 4.13 B | ||||
| Net Asset | 11.55 B | ||||
| Last Dividend Paid | 1.05 |
About Autobio Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Autobio Diagnostics Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Autobio Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Autobio Diagnostics Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Other Information on Investing in Autobio Stock
Autobio Diagnostics financial ratios help investors to determine whether Autobio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Autobio with respect to the benefits of owning Autobio Diagnostics security.